.After a handful of years in biotech, Mike Quigley, Ph.D., is actually coming back to the pharma layer, using up the top scientific research spot at Sanofi.Quigley will certainly start Sept. 30 as the French Big Pharma’s main clinical policeman and global head of research study, Sanofi said to Ferocious Biotech in an emailed claim.Quigley is actually switching out Frank Nestle, M.D., who left Sanofi this springtime surrounded by an international overhaul of the business’s R&D device. Nestle, that devoted eight years with the pharma, leapt over to Deerfield Administration, where he presently works as a partner on the therapies team and chief executive officer of the company’s curative discovery as well as growth functions.
Quigley is going to join Sanofi from a San Francisco-based biotech that remains in stealth, according to his LinkedIn profile page. He is actually presently noted as the business’s co-founder, head of state and also CEO.Considering that August 2021, Quigley has served as a venture companion at SV Health and wellness Investors, a healthcare fund manager along with present assets in biotechs like BioAge, Cerevance, Dualitas Therapies and also Nimbus Therapies, and many more. Quigley in the past held the best area at Dualitas, a biotech that stays in stealth, according to STAT.The prospective Sanofi innovator also previously helmed Therini Biography, an immunotherapy biotech working to create treatments for neurodegenerative diseases steered by general disorder.Just before spending the last few years in biotech, Quigley has an also longer record in Large Pharma, most just recently acting as Gilead’s elderly vice president of research study biology till the summertime of 2021.
Prior to that, he appeared more than 4 years throughout numerous leadership tasks at Bristol Myers Squibb and also served as a scientific director at Johnson & Johnson’s Janssen arm before that.Sanofi pointed out Quigley’s mission in his brand-new part would certainly be to “optimize our possibility of success through ideal partnerships all over our company and past, taking best-in-class technology and also establishing as well as sourcing brand-new industry-leading talent along with a commitment to variety,” depending on to an internal memorandum acquired by STAT.